ArticleBMC microbiology2025
Novel cationic peptide OB1111 is a dual anti-planktonic and anti-biofilm agent against P. aeruginosa strains PA14 and PAO1.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Peptides: Comparing Synthetic and Sequence-Engineered Antibiofilm Pharmaceutics.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa is a Gram-negative pathogen frequently responsible for nosocomial infections and a significant problem in intensive care units. P. aeruginosa, as an opportunistic pathogen, increases mortality risks for severely wounded and immunocompromised individuals. The inherent drug-resistance of P. aeruginosa now requires novel therapeutics with multiple mechanisms that will offer lasting potency in the post-antibiotic era. Synthetic antimicrobial peptides (AMPs) are ideal, as their multiple modes of action slow resistance development. In this study, we investigated the potential of novel proprietary AMP OB1111 to effectively treat P. aeruginosa under standard antimicrobial susceptibility testing (AST) and host-mimicking conditions, in planktonic and biofilm states, and at sublethal and lethal concentrations.
resultsThe highly virulent PA14 and moderately virulent PAO1 reference strains were used in these studies. OB1111 effectively displayed inhibitory and bactericidal activity against both strains under AST conditions in planktonic and biofilm states. OB1111 demonstrated anti-virulence activity under host-mimicking conditions by reducing pyoverdine production and early biofilm attachment at sublethal concentrations. Under AST conditions, sublethal doses of OB1111 gradually reduced planktonic PA14 and PAO1 growth but showed less efficacy against biofilms. Additionally, PAO1 biofilms showed reduced susceptibility to OB1111 in comparison to PA14 biofilms at sublethal concentrations. Of significance, scanning electron microscopy revealed that OB1111 effectively deformed and disintegrated PA14 and PAO1 membranes in both the planktonic and biofilm states.
conclusionsOB1111 successfully demonstrated the capacity to combat P. aeruginosa as an anti-planktonic, anti-biofilm, and anti-virulence agent. Future studies should further examine specific mechanisms of action against PA14 and PAO1, along with testing against clinical isolates in AST and host-mimicking conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.